Spinal Decompression Therapy Research in Chicago
Numerous research studies have been completed on VAX-D. Seven have been published in juried medical journals and an eighth soon will be. While each examines a different aspect of the VAX-D procedure, the conclusions are the same: VAX-D is a valid, consistently effective treatment protocol “ and a safe alternative to surgery. The following is a list of these studies, along with their notable conclusions:
1. œEffects of Vertebral Axial Decompression on Intradiscal Pressure, Gustavo Ramos, MD and William Martin, MD, Journal of Neurosurgery, 81:350-353, Sept. 1994.
Conclusion: œ. . . it is possible to lower pressure in the nucleus pulposis of herniated discs below 0mm Hg when distraction tension is applied according to the protocol described for vertebral axial decompression therapy.
2. œVertebral Axial Decompression Therapy for Pain Associated with Herniated or Degenerated Discs or Facet Syndrome: An outcome study, Earl E. Gose, Ph d, William K. Naguszewski, MD and Robert K. Naguszewski, MD, Journal of Neurological Research, Vol. 20, No 3, April 1998.
Conclusion: œVAX-D by its unique design may more precisely address the physiology of persistent low back pain than other conventional therapies. We consider it to be a front line treatment for degenerative spondylosis, facet syndrome, disc disease, and non-surgical lumbar radiculopathy.
3. œA Prospective Randomized Controlled Study of VAX-D and TENS for the Treatment of Chronic Low Back Pain, Eugene Sherry, MD, Senior Lecturer in Orthopedics, Sydney University, Peter Kitchner, MD, and Russell Smart, Journal of Neurological Research, Vol. 23, No 7, October 2001.
Conclusion: œThe results of this prospective study demonstrate that VAX-D can achieve a statistically significant improvement in pain and functional outcome for patients suffering from disc-related chronic low back pain.
4. œDermatomal Somatosensory Evoked Potential Demonstration of Nerve Root Decompression After VAX-D Therapy, William K. Naguszewski, MD, Robert K. Naguszewski, MD and Earl E. Gose, Ph d, Journal of Neurological Research, Vol. 23, No 7, October 2001.
Conclusion: œVAX-D therapy, however, addresses both primary and secondary causes of low back and referred pain. We thus submit that VAX-D therapy should be considered first, before the patient undergoes a surgical procedure which permanently alters the anatomy and function of the affected lumbar spine segment.
5. œThe Effects of Vertebral Axial Decompression On Sensory Nerve Dysfunction in Patients with Low Back Pain and Radiculopathy, Frank Tilaro, MD and DennisMuskovich, MD,Canadian Journal of Clinical Medicine, Vol. 6, No 1, January 1998
Conclusion: œFourteen of twenty-two peripheral nerves (64%) showing abnormal dysfunction secondary to compressive radiculopathy returned to normal function after therapeutic course of VAX-D therapy. The data from this study implies that VAX-D therapy is capable of influencing sensory nerve dysfunction associated with a compressive radiculopathy.
6. œEfficacy of VAX-D on Chronic Low Back Pain: Study of a Dosage Regimen, Gustavos Ramos, MD, Dept of Neurosurgery and Radiology, Rio Grande Regional Hospital, McAllen, Texas, accepted for publication, Journal ofNeurological Research, Vol. 26, April 2004.
Conclusion: œVAX-D should be utilized in all patients who are poor surgical candidates and before surgery is undertaken except in the emergent conditions.
7. œAn Overview of Vertebral Axial Decompression, Frank Tilaro, MD, Canadian Journal of Clinical Medicine, Vol. 5, No. 1, January 1998.
Conclusion: œVAX-D therapy addresses the biochemical aspects of discogenic and achieves its objective through decompression. It should be utilized in patients with low back pain with or without radiculopathy who have failed conventional therapy (physiotherapy and chiropractic), and should be utilized prior to addressing surgery.
8. œVAX-D Reduces Chronic Discogenic Low Back Pain “ 4 Year Study, Robert Odell, MD and Daniel Boudreau, DO, Anesthesiology News, Vol. 29, No 3, March 2003.
Conclusion:Of the 23 patients who responded [to the study questionnaire], 52% had a pain level of zero, 91% were able to resume their normal daily activities, and 87% were either working or were retired without having back pain as the cause for retirement “ œand there were no complications with this treatment.
10. œMedical Technologies Group Special Report on VAX-D, MTG News, Vol. 4, No 8, August 1995. [MTG is a medical review group that examines medical procedures, drugs and treatment protocols and makes recommendations to insurance companies.]
Conclusion: œCoupled with modern imaging technology that recorded modifications in the extent of herniated discs with VAX-D therapy, no other non-interventional means of treating low back pain, mechanical or otherwise, has shown such promise. MTG recommends the FDA approved VAX-D therapy for those patients who meet patient selection criteria.
11. œAn Industry-Based, Retrospective, Cost Analysis of Vertebral Axial Decompression (VAX-D) “ vs. “ Surgery for Lumbar Disc Disease: 10 Case Studies, David Duncan, MD and Don Keenan, Ph d (Sinclair Oil Corporation Study, Tulsa Oklahoma). Publication Pending.
Conclusion: The average cost to industry for a patient™s VAX-D treatments alone is $3,500-4,500. The average cost for a patient™s surgery alone is $12,000-65,000 (depending on surgical procedure performed.
Complete copies of the all of the research studies listed above are available upon request.
VAX-D: CLINICAL RESEARCH
Outcomes After a Prone Lumbar Traction Protocol for Patients With Activity-Limiting Low Back Pain: A Prospective Case Series Study
Paul F. Beattie, PhD, PT, OCS, Roger M. Nelson, PhD, PT, Lori A. Michener, PhD, PT, ATC, SCS, Joseph Cammarata, DC, Jonathan Donley, DPT
Archives of Physical Medicine And Rehabilitation, Volume 89, February 2008
Short And Long-Term Outcomes Following Treatment with the VAX-D Protocol for Patients with Chronic, Activity Limiting Low Back Pain
Beattie PF., Nelson R., Michener L., Cammarata J., Donely J.
Journal of Orthopaedic& Sports Physical Therapy, Volume 35, Number 1, January 2005
Efficacy of Vertebral Axial Decompression (VAX-D) on Chronic Low Back Pain: A Study of Dosage Regimen
Ramos G., MD,
Journal of Neurological Research, Volume 26, April 2004
Effects of Vertebral Axial Decompression On Intradiscal Pressure
Ramos G., MD, Martin W., MD,
Journal of Neurosurgery 81: 350-353, 1994
A Prospective Randomized Controlled Study of VAX-D and TENS for the Treatment of Chronic Low Back Pain
Sherry E., MD FRACS, Kitchener P., MB, BS FRANZCR, Smart R., MB, Ch.B
Journal of Neurological Research Volume 23, No 7, October 2001
Vertebral Axial Decompression Therapy for Pain Associated with Herniated or Degenerated Discs or Facet Syndrome: An Outcome Study
Gose E., Ph.D, Naguszewski W., MD, Naguszewski R., MD,
Journal of Neurological Research, Volume 20, No 3, April 1998.
Dermatosomal Somatosensory Evoked Potential Demonstration of Nerve Root Decompression After VAX-D Therapy
Naguszewski W., MD, Naguszewski R., MD, Gose E., Ph.D
Journal of Neurological Research Vol23 , No 7, October 2001
The Effects of Vertebral Axial Decompression On Sensory Nerve Dysfunction In Patients with Low Back Pain and Radiculopathy
Tilaro F., MD, Miskovich D. MD
Canadian Journal of Clinical Medicine Vol. 6, No 1, January 1999
VAX-D Reduces Chronic Discogenic Low Back Pain- 4 year Study
Odell R., MD.Ph.D, Boudreau D. DO
Anesthesiology News, Volume 29, Number 3, March 2003
Prospective Randomized Study of VAX-D Therapy for Acute Low Back Distress
Peerless S., MD. FRCP, Meissner L., MD, FRCP
Barnett H. J.M., MD. FRCP, Stiller C. R., MD, FRCP
The John P. Robarts Institute, University Hospital at London
University of Western Ontario, Canada
An Industry Based, Retrospective, Cost Analysis of Vertebral Axial Decompression (VAX-D) VS. Surgery For Lumbar Disc Disease: 10 Case Studies
David C. Duncan, MD, Don Keenan, SPHR, Ph.D.
Sinclair Oil Corporation Study, Tulsa Oklahoma
An Overview of Vertebral Axial Decompression
Tilaro F., MD
Canadian Journal of Clinical Medicine Vol. 5, No 1, January 1998
VAX-D: CLINICAL RESEARCH: TEXT BOOKS
Practice of Minimally Invasive Spinal Technique, 2006 Edition
Martin H Savitz, M.D., Ph.D., F.A.C.S., F.I.C.S., F.R.C.S. (US)
John C. Chiu, M.S., D.Sc., F.R.C.S. (US), F.I.C.S.
Wolfgang Rauschning, M.D., Ph.D.
Anthony T. Yeung, M.D., F.A.B.M.I.S.S.
Chapter 35;VAX-D (Vertebral Axial Decompression)
American Academy of Minimally Invasive Spinal Medicine and Surgery
Richmond, VA : AAMISMS Education, 
VAX-D: CLINICAL RESEARCH: ARTICLES
Vertebral Axial Decompression
European Musculoskelatal Review 2007 ; Issue 2
Orthopaedics: New answers to an age-old problem.
Hospital Management International 2004;
Annual Issue of the International Hospital Federation Journal, March 1, 2004
Welcome Relief for Low Back Pain
Stewart J. CBS Health Watch
Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School
Back Pain Abhors a Vacuum
Best™s Review- Life / Health; A.M. Best Company, Insurance Issues and Analysis, September 1998
The Treatment of Discogenic Low Back Pain: An Integrated Approach (VAX-D- Vertebral Axial Decompression Therapy)
Tilaro F., MD.
The McKenzie North American Conference, June 2-4 2000
VAX-D Outcome Study Results
Medical Technologies Group Newsletter
Advisors to the Insurance Industry
Volume 5, Number 15, November 1996
MTG ˜s Special Report On VAX-D
Medical Technologies Group Newsletter
Advisors to the Insurance Industry
Volume 4, Number 8, August 1995
Learn why our back pain service, such as VAX-D, are top of the line and will lead you back to comfort.